Phase II Study of Irinotecan plus S-1 in Treatment of Advanced Gastric Cancer
Phase II Study of Irinotecan plus S-1 in Treatment of Advanced Gastric Cancer作者机构：Department of Surgery Kanto Rosai Hospital Kawasaki Japan Department of Surgery University Hospital of Mizonokuchi Teikyo University School of Medicine Kawasaki Japan Institute of Gastroenterology Nippon Medical School Musashi Kosugi Hospital Kawasaki Japan
出 版 物：《Journal of Cancer Therapy》 (癌症治疗（英文）)
年 卷 期：2013年第4卷第2期
页 面：578-583页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Advanced Gastric Cancer Systemic Chemotherapy Irinotecan S-1
摘 要：Objective: The efficacy and safety of irinotecan hydrochloride (CPT-11) plus oral fluoropyrimidine S-1 combination therapy in patients with previously untreated advanced gastric cancer was evaluated. Methods: The regimen comprised CPT-11 plus S-1: CPT-11, 60 mg/m2 (days 1, 15);S-1, 40 - 60 mg/body twice daily (days 1 - 21) followed by a 1-week rest, every 4 weeks. Primary endpoint was response rate. Secondary endpoints were tumor control rate, adverse events, relative dose intensity, and overall survival. Results: Twenty-five patients were enrolled;median age was 66 years. Response rate was 40% (95% confidence interval, 21.1% - 61.3%;complete response in 1;partial response in 9). Tumor control rate was 56.0%, median survival time was 436 days and relative dose intensities were 0.83 for CPT-11 and 0.85 for S-1. Incidence of grade 3 or greater neutropenia, anemia and diarrhea was 16%, 12%, and 12%, ***: The present results indicate that CPT-11 plus S-1 offers lower treatment-related toxicity than regimens including cisplatin and is effective in patients with advanced gastric cancer.
维普期刊数据库